Comparative study of SGLT2 inhibitors and metformin: Evaluating first-line therapies for dementia prevention in type 2 diabetes - PubMed
6 hours ago
- #Type 2 Diabetes
- #SGLT2 Inhibitors
- #Dementia Prevention
- Type 2 diabetes (T2D) raises dementia risk by 1.5 to 2.5 times.
- SGLT2 inhibitors (SGLT2is) and metformin are antidiabetic drugs with neuroprotective potential.
- This retrospective cohort study used TriNetX data to compare SGLT2i vs. metformin as first-line therapy in T2D patients.
- Propensity score-matched cohorts (74,975 each) showed SGLT2i associated with lower overall dementia incidence: 2.7% vs. 6.9% (aHR 0.80).
- SGLT2i also reduced vascular dementia (aHR 0.87), Alzheimer's dementia (aHR 0.76), and all-cause mortality (aHR 0.92).
- Benefits were more pronounced in older adults, especially those aged ≥80 years.
- Conclusions suggest SGLT2is may offer superior neuroprotective benefits over metformin for dementia prevention in T2D.
- Further randomized trials are needed to confirm these results.